
Vivek Subbiah/LinkedIn
Mar 5, 2025, 07:35
The transformative odyssey of Tumour Agnostic Drug Development in Precision Medicine – ESMO
ESMO (European Society for Medical Oncology) shared a post on LinkedIn:
“ESMOTAT25: The transformative odyssey of Tumour Agnostic Drug Development in Precision Medicine.
Vivek Subbiah, MD discusses the paradigm shift away, at least partially, from organ-based treatment to molecularly guided treatment across tumour types. He describes how regulatory shifts and greater access to tumour profiling are now needed to realise their full benefits for patients.
To learn more, read the Opinion piece in the ESMO Daily Reporter.”
More posts featuring ESMO.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 5, 2025, 07:32
Mar 5, 2025, 07:22
Mar 5, 2025, 07:21
Mar 5, 2025, 07:08
Mar 5, 2025, 07:01